Biohaven Ltd. (NYSE:BHVN) Director John W. Childs Purchases 32,700 Shares

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs acquired 32,700 shares of the stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average cost of $30.47 per share, with a total value of $996,369.00. Following the transaction, the director now directly owns 2,320,571 shares in the company, valued at $70,707,798.37. This trade represents a 1.43 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Biohaven Trading Down 1.9 %

Shares of BHVN opened at $30.37 on Friday. The firm’s fifty day simple moving average is $37.98 and its 200-day simple moving average is $42.58. Biohaven Ltd. has a twelve month low of $26.80 and a twelve month high of $62.21. The firm has a market capitalization of $3.07 billion, a price-to-earnings ratio of -3.25 and a beta of 1.27.

Biohaven (NYSE:BHVN) last announced its quarterly earnings results on Monday, March 3rd. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.29). On average, analysts predict that Biohaven Ltd. will post -8.9 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have commented on BHVN. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price target on shares of Biohaven in a research report on Tuesday. TD Cowen raised their price target on shares of Biohaven from $55.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. JPMorgan Chase & Co. decreased their price target on shares of Biohaven from $72.00 to $68.00 and set an “overweight” rating for the company in a research report on Wednesday. HC Wainwright reissued a “buy” rating and issued a $54.00 price target on shares of Biohaven in a research report on Tuesday. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Tuesday, December 17th. Fourteen equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Biohaven currently has an average rating of “Buy” and an average target price of $62.77.

Institutional Investors Weigh In On Biohaven

Several hedge funds and other institutional investors have recently bought and sold shares of BHVN. US Bancorp DE raised its stake in Biohaven by 57.1% during the 3rd quarter. US Bancorp DE now owns 2,173 shares of the company’s stock worth $109,000 after acquiring an additional 790 shares in the last quarter. SpiderRock Advisors LLC acquired a new stake in Biohaven during the 3rd quarter worth $620,000. Venturi Wealth Management LLC raised its stake in Biohaven by 19.1% during the 3rd quarter. Venturi Wealth Management LLC now owns 3,117 shares of the company’s stock worth $156,000 after acquiring an additional 500 shares in the last quarter. Victory Capital Management Inc. raised its stake in Biohaven by 67.1% during the 3rd quarter. Victory Capital Management Inc. now owns 363,615 shares of the company’s stock worth $18,170,000 after acquiring an additional 145,960 shares in the last quarter. Finally, KBC Group NV raised its stake in Biohaven by 24.5% during the 3rd quarter. KBC Group NV now owns 2,250 shares of the company’s stock worth $112,000 after acquiring an additional 443 shares in the last quarter. 88.78% of the stock is currently owned by institutional investors and hedge funds.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.